Fennec Pharmaceuticals (FENC) Enterprise Value (2010 - 2026)

Fennec Pharmaceuticals (FENC) has 16 years of Enterprise Value data on file, last reported at -$36.8 million in Q4 2025.

• Quarterly Enterprise Value fell 38.12% year-over-year to -$36.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$36.8 million (down 38.12% YoY) and the FY2025 annual result came in at -$36.8 million, down 38.12% from the prior year.
• Enterprise Value eased to -$36.8 million in Q4 2025, from -$21.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$12.4 million in Q3 2023 to a low of -$51.2 million in Q1 2024.
• A 5-year average of -$25.1 million and a median of -$23.2 million in 2022 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2023 — Enterprise Value jumped 58.33% — and 2024, when it plunged 285.74%.
• Tracing FENC's Enterprise Value over 5 years: stood at -$21.1 million in 2021, then declined by 12.67% to -$23.8 million in 2022, then jumped by 44.19% to -$13.3 million in 2023, then slumped by 100.72% to -$26.6 million in 2024, then tumbled by 38.12% to -$36.8 million in 2025.
• The last three Enterprise Value figures came in at -$36.8 million (Q4 2025), -$21.9 million (Q3 2025), and -$18.7 million (Q2 2025), per Business Quant data.